EFEKTIVITAS DAN EFEK SAMPING DARI IMPLAN LEVONORGESTREL DAN IMPLAN ETONOGESTREL: REVIEW ARTICLE

Authors

  • Lutfi Chabib a:1:{s:5:"en_US";s:27:"Universitas Islam Indonesia";}
  • M. Pandoman febrian
  • Hannie Fitriani
  • Uzulul Hikmah

Keywords:

Implan, Levonorgestel, Etonogestrel, Efikasi, Efek Samping

Abstract

Implan levonorgestrel (LVN) dan etonogestrel (ENG) merupakan contoh long-acting reversible contraception (LARC) yang memiliki efektifitas yang tinggi dalam pencegahan kehamilan pada jangka waktu yang panjang. Penulisan review ini bertujuan untuk membandingkan efektifitas dan efek samping terkait LVN 2 batang dan ENG 1 batang sebagai alat kontrasepsi implan subdermal. Studi mengenai perbandingan efikasi implan LVN dengan implan ENG menunjukkan bahwa keduanya memiliki efikasi sebagai kontrasepsi yang baik diamati dari tingkat kejadian kehamilan yang sangat rendah. Perbedaan antara keduanya dapat dilihat dari berapa lama durasi yang disetujui untuk perlindungan dalam pencegahan kehamilan yaitu 3 tahun untuk implan ENG dan 5 tahun untuk implan LVN. Selain itu, Efektivitas kedua implan tersebut dalam mencegah kehamilan menunjukkan efek yang sebanding dari berbagai pengujian. Terkait studi mengenai efek samping menunjukkan bahwa efek samping pendarahan pada penggunaan ENG lebih besar dibandingkan pada implan LVN, sehingga LVN lebih dipilih dibandingkan dengan ENG.

References

Bahamondes L, Fernandes A, Monteiro I, Bahamondes MV. Long-acting reversible contraceptive (LARCs) methods. Best Pract Res Clin Obstet Gynaecol. 2020 Jul;66:28–40.

2. Roberts O, Rajoli RKR, Back DJ, Owen A, Darin KM, Fletcher C V, et al. Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug–drug interactions between levonorgestrel contraceptive implans and efavirenz-based ART. J Antimicrob Chemother. 2018 Apr 1;73(4):1004–12.

3. Croxatto HB. Mechanisms that explain the contraceptive action of progestin implans for women. Contraception. 2002 Jan;65(1):21–7.

4. Peralta O, Diaz S, Croxatto H. Subdermal contraceptive implans. J Steroid Biochem Mol Biol. 1995 Jun;53(1–6):223–6.

5. Contraceptive implan - NHS [Internet]. [cited 2022 Aug 28]. Available from: https://www.nhs.uk/conditions/contraception/contraceptive-implan/

6. Rocca ML, Palumbo AR, Visconti F, Di Carlo C. Safety and Benefits of Contraceptives Implans: A Systematic Review. Pharmaceuticals. 2021 Jun 8;14(6):548.

7. Drugs and Lactation Database. Levonorgestrel Implan Drug Levels and Effects Effects in Breastfed Infants. Natl Libr Med. 2021;(Md):1–5.

8. Mishell DR. Contraception. In: Goldman’s Cecil Medicine. Elsevier; 2012. p. 1552–5.

9. Ali M, Bahamondes L, Bent Landoulsi S. Extended Effectiveness of the Etonogestrel-Releasing Contraceptive Implan and the 20 µg Levonorgestrel-Releasing Intrauterine System for 2 Years Beyond U.S. Food and Drug Administration Product Labeling. Glob Health Sci Pract. 2017;5(4):534–9.

10. Schreiber CA, Barnhart K. Contraception. In: Yen & Jaffe’s Reproductive Endocrinology. Elsevier; 2014. p. 890-908.e3.

11. Hormonal contraceptives—progestogen implans. In: Meyler’s Side Effects of Drugs. Elsevier; 2016. p. 830–5.

12. Hubacher D, Spector H, Monteith C, Chen PL, Hart C. Long-acting reversible contraceptive acceptability and unintended pregnancy among women presenting for short-acting methods: a randomized patient preference trial. Am J Obstet Gynecol. 2017 Feb;216(2):101–9.

13. Ali M, Akin A, Bahamondes L, Brache V, Habib N, Landoulsi S, et al. Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implan: comparison to levonorgestrel-releasing subdermal implan. Hum Reprod. 2016 Nov;31(11):2491–8.

14. Steiner MJ, Lopez LM, Grimes DA, Cheng L, Shelton J, Trussell J, et al. Sino-implan (II) — a levonorgestrel-releasing two-rod implan: systematic review of the randomized controlled trials. Contraception. 2010 Mar;81(3):197–201.

15. Ramdhan RC, Simonds E, Wilson C, Loukas M, Oskouian RJ, Tubbs RS. Complications of Subcutaneous Contraception: A Review. Cureus. 2018 Jan 31;10(1):e2132.

16. Levonorgestrel [Internet]. [cited 2022 Sep 27]. Available from: https://go.drugbank.com/drugs/DB00367

17. Sivasankaran S, Jonnalagadda S. Advances in controlled release hormonal technologies for contraception: A review of existing devices, underlying mechanisms, and future directions. J Controlled Release. 2021 Feb;330:797–811.

18. Friend DR. Development of controlled release systems over the past 50 years in the area of contraception. J Controlled Release. 2016 Oct;240:235–41.

19. Pam V, Mutihir J, Nyango D, Shambe I, Egbodo C, Karshima J. Sociodemographic profiles and use-dynamics of Jadelle (levonorgestrel) implans in Jos, Nigeria. Niger Med J. 2016;57(6):314.

20. Glasier A. Contraception. In: Endocrinology: Adult and Pediatric. Elsevier; 2016. p. 2297-2309.e2.

21. Olsson SE, Odlind V, Johansson EDB, Sivin I. Contraception with norplant® implans and NORPLANT®-2 implans (two covered rods). Contraception. 1988 Jan;37(1):61–73.

22. Gunardi ER, Affandi B. Serum levonorgestrel concentration and cervical mucus viscosity after six months of monoplant® implanation. Med J Indones. 2014 Mar 11;25.

23. Sinoplant – Catur Dakwah [Internet]. [cited 2022 Sep 27]. Available from: https://www.caturdakwah.com/sinoplant/

24. Maddox DD, Rahman Z. Etonogestrel (Implanon), Another Treatment Option for Contraception. Pharm Ther. 2008;33(6):337.

25. Moray K V, Chaurasia H, Sachin O, Joshi B. A systematic review on clinical effectiveness, side-effect profile and meta-analysis on continuation rate of etonogestrel contraceptive implan. Reprod Health. 2021 Jan 6;18(1):4.

26. Hickey M, Kaunitz AM. Hormonal Contraception. In: Williams Textbook of Endocrinology. Elsevier; 2011. p. 661–87.

27. Etonogestrel [Internet]. [cited 2022 Sep 27]. Available from: https://go.drugbank.com/drugs/DB00294

28. Hormonal contraceptives—progestogen implans - ClinicalKey [Internet]. [cited 2022 Aug 28]. Available from: https://www.clinicalkey.com/#!/content/book/3-s2.0-B9780444537171008556

29. Vo M. Long-Acting Reversible Contraception in Adolescents. In: Reference Module in Biomedical Sciences. Elsevier; 2021.

30. Etonogestrel: Manfaat, Dosis dan Efek Samping [Internet]. [cited 2022 Sep 27]. Available from: https://aido.id/health-articles/etonogestrel/detail

31. Bhatia P, Nangia S, Aggarwal S, Tewari C. Implanon: subdermal single rod contraceptive implan. J Obstet Gynaecol India. 2011 Aug;61(4):422–5.

32. Cooling H, Pauli H. Full-term pregnancy with Implanon® in situ. J Fam Plann Reprod Health Care. 2006 Jul 1;32(3):204–204.

33. Flores JBO, Balderas ML, Bonilla MC, Vázquez-Estrada L. Clinical experience and acceptability of the etonogestrel subdermal contraceptive implan. Int J Gynecol Obstet. 2005 Sep;90(3):228–33.

34. McNicholas C, Swor E, Wan L, Peipert JF. Prolonged use of the etonogestrel implan and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration–approved duration. Am J Obstet Gynecol. 2017 Jun;216(6):586.e1-586.e6.

35. Dugré N, Choksi N, Kirkwood J. Etonogestrel implan effectiveness. Can Fam Physician Med Fam Can. 2022 Aug;68(8):594.

36. Coukell AJ, Balfour JA. Levonorgestrel subdermal implans. A review of contraceptive efficacy and acceptability. Drugs. 1998 Jun;55(6):861–87.

37. Bahamondes L, Brache V, Meirik O, Ali M, Habib N, Landoulsi S. A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implans, with non-randomized matched copper-intrauterine device controls. Hum Reprod. 2015 Nov;30(11):2527–38.

38. Shoupe D, Mishell DR. Contraception. In: Women and Health. Elsevier; 2013. p. 209–34.

39. Villavicencio J, Allen RH. Unscheduled bleeding and contraceptive choice: increasing satisfaction and continuation rates. Open Access J Contracept. 2016;7:43–52.

40. Hubacher D, Lopez L, Steiner MJ, Dorflinger L. Menstrual pattern changes from levonorgestrel subdermal implans and DMPA: systematic review and evidence-based comparisons. Contraception. 2009 Aug;80(2):113–8.

41. Haslan H, Indryani I. Hubungan Penggunaan KB Implan dengan Berat Badan dan Siklus Haid Akseptor KB. J Ilm Kesehat Sandi Husada. 2020 Jun 30;11(1):347–52.

42. Bahamondes L, Brache V, Ali M, Habib N. A multicenter randomized clinical trial of etonogestrel and levonorgestrel contraceptive implans with nonrandomized copper intrauterine device controls: effect on weight variations up to 3 years after placement. Contraception. 2018 Sep;98(3):181–7.

Downloads

Published

2023-12-31

Issue

Vol. 27 No. 3 (2023): MFF

Section

Articles

License

Copyright (c) 2023 Majalah Farmasi dan Farmakologi

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

The copyright to this article is transferred to Universitas Hasanuddin (UNHAS) if and when the article is accepted for publication. The undersigned hereby transfers all rights in and to the paper including without limitation all copyrights to UNHAS. The undersigned hereby represents and warrants that the paper is original and that he/she is the author of the paper, except for material that is clearly identified as to its original source, with permission notices from the copyright owners where required. The undersigned represents that he/she has the power and authority to make and execute this assignment.

We declare that:

  1. This paper has not been published in the same form elsewhere.
  2. It will not be submitted anywhere else for publication prior to acceptance/rejection by this Journal.
  3. A copyright permission is obtained for materials published elsewhere and which require this permission for reproduction.

Furthermore, I/We hereby transfer the unlimited rights of publication of the above-mentioned paper in whole to UNHAS The copyright transfer covers the exclusive right to reproduce and distribute the article, including reprints, translations, photographic reproductions, microform, electronic form (offline, online) or any other reproductions of similar nature.

The corresponding author signs for and accepts responsibility for releasing this material on behalf of any and all co-authors. This agreement is to be signed by at least one of the authors who have obtained the assent of the co-author(s) where applicable. After submission of this agreement signed by the corresponding author, changes of authorship or in the order of the authors listed will not be accepted.